Kestra Medical Technologies (NASDAQ:KMTS) Insider Sells $304,050.00 in Stock

Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) insider Brian Daniel Webster sold 15,000 shares of the company’s stock in a transaction that occurred on Tuesday, March 17th. The stock was sold at an average price of $20.27, for a total transaction of $304,050.00. Following the sale, the insider directly owned 364,786 shares of the company’s stock, valued at approximately $7,394,212.22. This trade represents a 3.95% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.

Brian Daniel Webster also recently made the following trade(s):

• On Tuesday, February 17th, Brian Daniel Webster sold 15,000 shares of Kestra Medical Technologies stock. The stock was sold at an average price of $25.60, for a total transaction of $384,000.00.
• On Thursday, January 15th, Brian Daniel Webster sold 15,000 shares of Kestra Medical Technologies stock. The shares were sold at an average price of $22.80, for a total transaction of $342,000.00.
• On Monday, December 29th, Brian Daniel Webster sold 15,000 shares of Kestra Medical Technologies stock. The shares were sold at an average price of $26.59, for a total transaction of $398,850.00.

Kestra Medical Technologies Stock Down 2.4%

NASDAQ KMTS opened at $19.10 on Friday. The business has a fifty day moving average price of $23.94 and a two-hundred day moving average price of $24.58. The stock has a market capitalization of $1.11 billion and a PE ratio of -4.82. Kestra Medical Technologies, Ltd. has a fifty-two week low of $13.25 and a fifty-two week high of $30.00. The company has a debt-to-equity ratio of 0.15, a current ratio of 7.32 and a quick ratio of 5.47.

Kestra Medical Technologies (NASDAQ:KMTS) last issued its quarterly earnings results on Tuesday, March 17th. The company reported ($0.61) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.60) by ($0.01). Kestra Medical Technologies had a negative net margin of 171.87% and a negative return on equity of 65.49%. The business had revenue of $24.55 million during the quarter. The business’s revenue for the quarter was up 62.7% on a year-over-year basis.

Analysts Set New Price Targets

Several research analysts have commented on KMTS shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Kestra Medical Technologies in a research note on Wednesday, December 24th. Piper Sandler lifted their price target on shares of Kestra Medical Technologies from $27.00 to $30.00 and gave the company an “overweight” rating in a report on Friday, December 12th. Stifel Nicolaus set a $30.00 price objective on shares of Kestra Medical Technologies in a research report on Friday, December 12th. Wells Fargo & Company increased their price objective on shares of Kestra Medical Technologies from $27.00 to $28.00 and gave the company an “overweight” rating in a research note on Friday, December 12th. Finally, The Goldman Sachs Group set a $24.00 target price on shares of Kestra Medical Technologies in a research report on Friday, January 16th. Six investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $29.00.

Institutional Trading of Kestra Medical Technologies

A number of hedge funds have recently made changes to their positions in KMTS. Franklin Resources Inc. raised its holdings in Kestra Medical Technologies by 32.4% during the 2nd quarter. Franklin Resources Inc. now owns 441,398 shares of the company’s stock worth $7,318,000 after purchasing an additional 108,103 shares during the last quarter. Brown Advisory Inc. increased its position in shares of Kestra Medical Technologies by 5.4% during the second quarter. Brown Advisory Inc. now owns 580,025 shares of the company’s stock worth $9,617,000 after buying an additional 29,607 shares during the period. Eventide Asset Management LLC increased its position in shares of Kestra Medical Technologies by 285.7% during the second quarter. Eventide Asset Management LLC now owns 1,060,557 shares of the company’s stock worth $17,584,000 after buying an additional 785,557 shares during the period. Police & Firemen s Retirement System of New Jersey bought a new position in Kestra Medical Technologies during the second quarter worth $54,000. Finally, Mirae Asset Global Investments Co. Ltd. acquired a new position in Kestra Medical Technologies in the third quarter valued at $562,000.

Kestra Medical Technologies Company Profile

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.